AR038142A1 - Agonistas del receptor 2 del factor liberador de la corticotropina - Google Patents
Agonistas del receptor 2 del factor liberador de la corticotropinaInfo
- Publication number
- AR038142A1 AR038142A1 ARP030100099A ARP030100099A AR038142A1 AR 038142 A1 AR038142 A1 AR 038142A1 AR P030100099 A ARP030100099 A AR P030100099A AR P030100099 A ARP030100099 A AR P030100099A AR 038142 A1 AR038142 A1 AR 038142A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- sequence
- peptide
- nothing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un péptido no nativo de fórmula: a-b-g-d-e-z-h-q, donde: a) a comprende una secuencia de fórmula X1X2X3X4X5X6; b) b comprende una secuencia de fórmula SX8X10; c) g comprende una secuencia de fórmula X11X12X13; d) d comprende una secuencia de fórmula X14X15X16; e comprende una secuencia de fórmula X17X18X19X20X21; z comprende una secuencia de fórmula X22X23X24X25; h comprende una secuencia de fórmula X26X27X28X29X30X31; e) q comprende una secuencia de fórmula X32X33NX35X36X37X38X39X40X41; donde Xi y los demás sustituyentes se definen en la Memoria, y variantes de los mismos; en donde las secuencias correspondientes se incluyen en la Memoria. Un método que comprende el uso de dicho péptido para evitar o tratar un trastorno modulado por CRF2R liberador de la corticotropina, como ser atrofia del músculo esquelético o distrofia muscular. Acido nucleico aislado que codifica dicho péptido y anticuerpo aislado específico para dicho péptido. Composición farmacéutica que comprende dicho péptido y un portador farmacéuticamente aceptable y kit o conjunto para evitar o tratar un trastorno modulado por CRF2R que comprende dicho péptido en forma de dosis unitaria e instrucciones de uso. Reivindicación 1: Un péptido no nativo según la fórmula: a-b-g-d-e-z-h-q en donde: a) a comprende una secuencia de una fórmula X1X2X3X4X5X6, en donde: X1X2 y X3 cada una se selecciona del grupo que consiste de nada, A, E, D, G, N, P, Q, S, T, y Z; X4 se selecciona del grupo que consiste de F, I, L, P, T y V; X5 se selecciona del grupo que consiste de A, I, P, S, T y V; X6 se selecciona del grupo que consiste de I, L, M y N; b) b comprende una secuencia de una fórmula SX8DX10, en donde: X8 y X10 cada una independientemente se selecciona del grupo que consiste de I, L y V; c) g comprende una secuencia de una fórmula X11X12X13, en donde: X11 se selecciona del grupo que consiste de P, S, V, y T; y X12 y X13 cada una independientemente se selecciona del grupo que consiste de A, Naftilalanina, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W e Y; d) d comprende una secuencia de una fórmula X14X15X16, en donde: X14 se selecciona del grupo que consiste de I, L y M; X15 se selecciona de L y M; y X16 se selecciona del grupo que consiste de S, N, Q, y R; e) e comprende una secuencia de una fórmula X17X18X19X20X21, en donde: X17 se selecciona del grupo que consiste de V, I, L, T, K, E, N, y Q; X18 se selecciona del grupo que consiste de L, M, V, A, y T; X19 se selecciona del grupo que consiste de I, F, L, y M; X20 se selecciona del grupo que consiste de D, E, N, y H; y X21 se selecciona del grupo que consiste de L, V, I, Q, M, y R; f) z comprende una secuencia de una fórmula X22X23X24X25, en donde: X22 se selecciona del grupo que consiste de nada, A, D, E, S, y T; X23 se selecciona del grupo que consiste de nada, K y R; X24 se selecciona del grupo que consiste de nada, A, H, M, N, Q, T, e Y; X25 se selecciona del grupo que consiste de nada, E, D, I, K, N, Q, y R; g) h comprende una secuencia de la fórmula X26X27X28X29X30X31, en donde: X26 se selecciona del grupo que consiste de A, D, G, H, K, N, Q, y S; X27 se selecciona del grupo que consiste de A, E, I, L, M, y Q; X28 se selecciona del grupo que consiste de A, K, H, Q, R, y V; X29 se selecciona del grupo que consiste de A, E, K, M, N, y Q; X30 se selecciona del grupo que consiste de H, K, N, Q, y R; X31 se selecciona del grupo que consiste de A y K; h) q comprende una secuencia de la fórmula X32X33NX35X36X37X38X39X40X41, en donde: X32 se selecciona del grupo que consiste de A, E, H y T; X33 se selecciona del grupo que consiste de A, D, E, I, L, N, Q R, S y T; X35 se selecciona del grupo que consiste de A y R; X36 se selecciona del grupo que consiste de E, H, I, K, L, N, Q y R; X37 se selecciona del grupo que consiste de F, I, L, M y Y; X38 se selecciona del grupo que consiste de L, F y M; X39 se selecciona del grupo que consiste de A, D, E, N y Q; X40 se selecciona del grupo que consiste de A, D, E, H, I, K, N, Q, R, S y T; X41 se selecciona del grupo que consiste de A, F, I y V; y variantes de éstos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34911702P | 2002-01-16 | 2002-01-16 | |
| US37633702P | 2002-04-29 | 2002-04-29 | |
| US38889502P | 2002-06-14 | 2002-06-14 | |
| US41198802P | 2002-09-19 | 2002-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038142A1 true AR038142A1 (es) | 2004-12-29 |
Family
ID=27617822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100100A AR038143A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
| ARP030100099A AR038142A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
| ARP030100101A AR038144A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100100A AR038143A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100101A AR038144A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US6936585B2 (es) |
| EP (4) | EP1465922B1 (es) |
| JP (3) | JP4508648B2 (es) |
| KR (3) | KR100735586B1 (es) |
| CN (3) | CN100475844C (es) |
| AR (3) | AR038143A1 (es) |
| AT (4) | ATE398632T1 (es) |
| AU (2) | AU2003205197B2 (es) |
| BR (3) | BR0306838A (es) |
| CA (3) | CA2470731C (es) |
| CY (1) | CY1106133T1 (es) |
| DE (4) | DE60321730D1 (es) |
| DK (2) | DK1465921T3 (es) |
| ES (4) | ES2299701T3 (es) |
| HK (1) | HK1078095A1 (es) |
| IL (5) | IL162530A0 (es) |
| MA (3) | MA27592A1 (es) |
| MX (3) | MXPA04006884A (es) |
| MY (1) | MY140306A (es) |
| NO (3) | NO20043366L (es) |
| NZ (3) | NZ533598A (es) |
| PE (3) | PE20030849A1 (es) |
| PL (3) | PL371364A1 (es) |
| PT (2) | PT1465921E (es) |
| RU (1) | RU2294333C2 (es) |
| SA (3) | SA03230565B1 (es) |
| SI (1) | SI1465921T1 (es) |
| TW (3) | TWI300442B (es) |
| WO (3) | WO2003062277A1 (es) |
| ZA (1) | ZA200404995B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2427490A1 (en) * | 2000-09-22 | 2002-03-28 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2005103690A2 (en) * | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) |
| EP1871888A4 (en) * | 2005-03-30 | 2013-08-21 | Novartis Vaccines & Diagnostic | HAEMOPHILUS INFLUENZAE TYPE B |
| WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
| US20100216722A1 (en) * | 2007-09-11 | 2010-08-26 | Dorian Bevec | Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| RU2010114038A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза |
| WO2009046874A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Therapeutic combination of trh-potentiating peptide and stresscopin |
| AU2009313619A1 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
| EP2206726A1 (en) * | 2009-01-08 | 2010-07-14 | Universite Joseph Fourier | Non-invasive tools for detecting vulnerable atherosclerotic plaques |
| AU2010315131A1 (en) * | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
| US9314506B2 (en) | 2011-10-24 | 2016-04-19 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| HUE036640T2 (hu) * | 2012-02-14 | 2018-07-30 | Univ California | Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra |
| JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| CA3040889A1 (en) * | 2016-10-20 | 2018-04-26 | Cortene Inc. | Methods of treating diseases resulting from a maladapted stress response |
| CN110755434B (zh) * | 2018-07-27 | 2022-03-15 | 中国医学科学院药物研究所 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235036A (en) * | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
| EP0860501A3 (en) | 1994-06-14 | 1999-05-19 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
| US5663292A (en) * | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5824771A (en) * | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| WO1997000063A2 (en) | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
| EP1305334B1 (en) | 2000-08-04 | 2008-09-17 | Research Development Foundation | Urocortin proteins and uses thereof |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US6936585B2 (en) | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
-
2002
- 2002-12-11 US US10/317,252 patent/US6936585B2/en not_active Expired - Lifetime
- 2002-12-11 US US10/317,251 patent/US7192924B2/en not_active Expired - Fee Related
- 2002-12-11 US US10/315,964 patent/US7192923B2/en not_active Expired - Fee Related
-
2003
- 2003-01-10 TW TW092100533A patent/TWI300442B/zh not_active IP Right Cessation
- 2003-01-10 TW TW092100535A patent/TW200302278A/zh unknown
- 2003-01-10 TW TW092100532A patent/TW200302276A/zh unknown
- 2003-01-14 PE PE2003000041A patent/PE20030849A1/es not_active Application Discontinuation
- 2003-01-14 PE PE2003000040A patent/PE20030974A1/es not_active Application Discontinuation
- 2003-01-14 PE PE2003000039A patent/PE20030747A1/es not_active Application Discontinuation
- 2003-01-15 MY MYPI20030136A patent/MY140306A/en unknown
- 2003-01-15 AR ARP030100100A patent/AR038143A1/es unknown
- 2003-01-15 AR ARP030100099A patent/AR038142A1/es unknown
- 2003-01-15 AR ARP030100101A patent/AR038144A1/es unknown
- 2003-01-16 AT AT06117810T patent/ATE398632T1/de not_active IP Right Cessation
- 2003-01-16 MX MXPA04006884A patent/MXPA04006884A/es active IP Right Grant
- 2003-01-16 AT AT03731965T patent/ATE362488T1/de not_active IP Right Cessation
- 2003-01-16 CA CA2470731A patent/CA2470731C/en not_active Expired - Fee Related
- 2003-01-16 EP EP03731963A patent/EP1465922B1/en not_active Expired - Lifetime
- 2003-01-16 IL IL16253003A patent/IL162530A0/xx unknown
- 2003-01-16 CN CNB038023520A patent/CN100475844C/zh not_active Expired - Fee Related
- 2003-01-16 KR KR1020047011051A patent/KR100735586B1/ko not_active IP Right Cessation
- 2003-01-16 JP JP2003562145A patent/JP4508648B2/ja not_active Expired - Fee Related
- 2003-01-16 EP EP03731965A patent/EP1465923B1/en not_active Expired - Lifetime
- 2003-01-16 PT PT03703867T patent/PT1465921E/pt unknown
- 2003-01-16 PT PT03731965T patent/PT1465923E/pt unknown
- 2003-01-16 ES ES03731963T patent/ES2299701T3/es not_active Expired - Lifetime
- 2003-01-16 NZ NZ533598A patent/NZ533598A/en unknown
- 2003-01-16 AT AT03731963T patent/ATE383372T1/de not_active IP Right Cessation
- 2003-01-16 KR KR1020047011052A patent/KR100758857B1/ko not_active IP Right Cessation
- 2003-01-16 MX MXPA04006883A patent/MXPA04006883A/es active IP Right Grant
- 2003-01-16 ES ES03731965T patent/ES2287484T3/es not_active Expired - Lifetime
- 2003-01-16 DK DK03703867T patent/DK1465921T3/da active
- 2003-01-16 ES ES03703867T patent/ES2269976T3/es not_active Expired - Lifetime
- 2003-01-16 RU RU2004124847/13A patent/RU2294333C2/ru active
- 2003-01-16 IL IL15252903A patent/IL162529A0/xx unknown
- 2003-01-16 PL PL03371364A patent/PL371364A1/xx unknown
- 2003-01-16 ES ES06117810T patent/ES2309909T3/es not_active Expired - Lifetime
- 2003-01-16 CN CNA038023709A patent/CN1617887A/zh active Pending
- 2003-01-16 PL PL03373139A patent/PL373139A1/xx not_active Application Discontinuation
- 2003-01-16 PL PL03373529A patent/PL373529A1/xx not_active Application Discontinuation
- 2003-01-16 DE DE60321730T patent/DE60321730D1/de not_active Expired - Lifetime
- 2003-01-16 WO PCT/US2003/001454 patent/WO2003062277A1/en active IP Right Grant
- 2003-01-16 AT AT03703867T patent/ATE334147T1/de not_active IP Right Cessation
- 2003-01-16 JP JP2003562154A patent/JP4489434B2/ja not_active Expired - Fee Related
- 2003-01-16 DK DK03731965T patent/DK1465923T3/da active
- 2003-01-16 BR BR0306838-2A patent/BR0306838A/pt not_active Application Discontinuation
- 2003-01-16 DE DE60313845T patent/DE60313845T2/de not_active Expired - Lifetime
- 2003-01-16 SI SI200330360T patent/SI1465921T1/sl unknown
- 2003-01-16 BR BR0306878-1A patent/BR0306878A/pt not_active IP Right Cessation
- 2003-01-16 AU AU2003205197A patent/AU2003205197B2/en not_active Ceased
- 2003-01-16 NZ NZ533599A patent/NZ533599A/en unknown
- 2003-01-16 EP EP03703867A patent/EP1465921B1/en not_active Expired - Lifetime
- 2003-01-16 AU AU2003237419A patent/AU2003237419B2/en not_active Ceased
- 2003-01-16 NZ NZ533600A patent/NZ533600A/en unknown
- 2003-01-16 JP JP2003562146A patent/JP4508649B2/ja not_active Expired - Fee Related
- 2003-01-16 CA CA2470743A patent/CA2470743C/en not_active Expired - Fee Related
- 2003-01-16 CN CNB038023644A patent/CN100391972C/zh not_active Expired - Fee Related
- 2003-01-16 DE DE60318547T patent/DE60318547T2/de not_active Expired - Lifetime
- 2003-01-16 EP EP06117810A patent/EP1724283B1/en not_active Expired - Lifetime
- 2003-01-16 WO PCT/US2003/001451 patent/WO2003062268A2/en active IP Right Grant
- 2003-01-16 IL IL16243103A patent/IL162431A0/xx unknown
- 2003-01-16 BR BR0306826-9A patent/BR0306826A/pt not_active IP Right Cessation
- 2003-01-16 WO PCT/US2003/001461 patent/WO2003062269A2/en active IP Right Grant
- 2003-01-16 MX MXPA04006885A patent/MXPA04006885A/es active IP Right Grant
- 2003-01-16 CA CA2470656A patent/CA2470656C/en not_active Expired - Fee Related
- 2003-01-16 DE DE60307044T patent/DE60307044T2/de not_active Expired - Lifetime
- 2003-01-16 KR KR1020047011057A patent/KR100758858B1/ko not_active IP Right Cessation
- 2003-03-01 SA SA3230565A patent/SA03230565B1/ar unknown
- 2003-03-01 SA SA3230564A patent/SA03230564B1/ar unknown
- 2003-03-01 SA SA03230564D patent/SA03230564A/ar unknown
-
2004
- 2004-06-24 ZA ZA2004/04995A patent/ZA200404995B/en unknown
- 2004-07-13 MA MA27780A patent/MA27592A1/fr unknown
- 2004-07-13 MA MA27779A patent/MA27591A1/fr unknown
- 2004-07-13 MA MA27778A patent/MA27590A1/fr unknown
- 2004-08-13 NO NO20043366A patent/NO20043366L/no not_active Application Discontinuation
- 2004-08-13 NO NO20043371A patent/NO20043371L/no not_active Application Discontinuation
- 2004-08-16 NO NO20043396A patent/NO20043396L/no not_active Application Discontinuation
-
2005
- 2005-05-04 US US11/121,612 patent/US7462597B2/en not_active Expired - Fee Related
- 2005-11-11 HK HK05110114A patent/HK1078095A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 CY CY20061101051T patent/CY1106133T1/el unknown
-
2007
- 2007-02-02 US US11/701,912 patent/US7632933B2/en not_active Expired - Fee Related
- 2007-02-02 US US11/701,576 patent/US7608701B2/en not_active Expired - Fee Related
-
2009
- 2009-01-07 IL IL196384A patent/IL196384A0/en unknown
- 2009-03-24 IL IL197774A patent/IL197774A0/en unknown
- 2009-10-26 US US12/605,718 patent/US7897731B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038142A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| IS7965A (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| EA200500299A1 (ru) | Пиразольные композиции, используемые в качестве ингибиторов gsk-3 | |
| CL2009000648A1 (es) | Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02). | |
| BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| ECSP066500A (es) | Pastas y varillas sólidas de fosfato de calcio inyectable para la liberación de proteínas osteogénicas | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
| CY1106357T1 (el) | Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| NO20052071L (no) | Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer. | |
| CR8274A (es) | Piridina, pirazina y pirimidinas fusionados con heteroarilos como receptores de crf1 | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| CY1112139T1 (el) | Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης | |
| IS2600B (is) | Ný tríasólpýrimídínefnasambönd | |
| EA201000496A1 (ru) | Замещенное соединение миноциклина, способ получения замещенных соединений миноциклина (варианты) | |
| EA200602196A1 (ru) | Производные пиразола, композиции, содержащие эти соединения, и способы применения | |
| CY1114241T1 (el) | Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| TNSN02039A1 (en) | RECONSTITUTABLE PARENTERAL COMPOSITION | |
| NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
| DK1517890T3 (da) | Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
| DE50304030D1 (de) | Verfahren zur Herstellung von 5-Nitrobenzofuranen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |